rs1279683 — SLC23A2

Intronic variant in the SVCT2 vitamin C transporter — G allele associated with lower plasma vitamin C, higher glaucoma risk, and modified cognitive decline risk in APOE4 carriers

See your personal result for SLC23A2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC23A2 rs1279683 — Vitamin C Delivery, Glaucoma Risk, and the SVCT2 Transporter

Vitamin C cannot synthesize itself — it must be obtained from food, absorbed by the gut, and then actively transported into individual cells. That last step is controlled by SVCT211 SVCT2
Sodium-dependent Vitamin C Transporter 2, encoded by SLC23A2 — the primary transporter moving ascorbate from the bloodstream into metabolically demanding tissues such as the brain, adrenal glands, and eyes. A common intronic variant at rs1279683 in SLC23A2 has been associated with meaningfully lower plasma vitamin C concentrations and a 67% increased risk of primary open-angle glaucoma in carriers of the G allele. Because SVCT2 is the dominant transporter for the retina, brain, and adrenal cortex — tissues that concentrate ascorbate to levels 10–100 times higher than plasma — this variant sits at the intersection of antioxidant defence, intraocular pressure regulation, and cognitive resilience.

The Mechanism

rs1279683 falls within an intron of SLC23A2 on chromosome 20 (GRCh38 position 5,002,446). SLC23A2 is transcribed from the minus strand. The variant's functional consequence is not characterized by in vitro assay, but intronic variants can alter pre-mRNA splicing efficiency22 pre-mRNA splicing efficiency
Intronic variants near splice regulatory elements or branch points can disrupt the recognition signals needed to join exons correctly, potentially reducing transporter protein output, local enhancer/silencer activity, or mRNA stability. The measurable reduction in plasma ascorbate in G allele carriers implies that this intronic position does influence SVCT2 expression or function in a detectable way.

SVCT2 is most highly expressed in the adrenal gland (RPKM 40.7) and brain (RPKM 20.8). It is the sole active transporter moving ascorbate across the blood-brain barrier and into the retinal ganglion cells. In the aqueous humor of the eye, ascorbate is present at concentrations up to 20-fold higher than plasma — a gradient maintained by SVCT2 activity in ciliary epithelial cells. That gradient is protective against oxidative damage to the trabecular meshwork, which regulates intraocular pressure. Reduced SVCT2 efficiency compresses this protective gradient and may contribute to glaucoma pathogenesis.

The Evidence

The strongest direct evidence comes from a Spanish case-control study33 Spanish case-control study
Zanon-Moreno V et al. Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population. Mol Vis, 2011 of 150 POAG cases and 150 controls. GG homozygotes had plasma vitamin C of 9.0 ± 1.4 µg/ml in cases compared to 10.5 ± 1.6 µg/ml in non-GG genotypes — a statistically significant 14% reduction. Among controls, GG subjects showed 10.9 vs 12.1 µg/ml. The GG genotype conferred an age- and sex-adjusted odds ratio for POAG of 1.67 (95% CI 1.03–2.71, p = 0.010).

The glaucoma association was replicated across a larger evidence base. A meta-analysis of 108 case-control studies44 meta-analysis of 108 case-control studies
Chen M et al. Association of Gene Polymorphisms With Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci, 2019 covering 35,389 POAG patients and 51,742 controls identified rs1279683 among 20 SNPs in 12 genes with consistent genome-wide significance.

A Japanese cohort study of 393 subjects examined vitamin C transporter variants and cognitive decline55 vitamin C transporter variants and cognitive decline
Hayashi K et al. Effects of functional variants of vitamin C transporter genes on apolipoprotein E E4-associated risk of cognitive decline: The Nakajima study. PLoS One, 2021. Minor allele carriers (i.e., individuals with at least one A allele) did not show elevated cognitive risk. However, among the subset also carrying APOE4, carrying the minor allele (A) was protective: APOE4 carriers who were GG homozygotes had substantially higher cognitive decline risk (OR 2.02, 95% CI 1.05–3.87) compared to APOE4 carriers with at least one A allele. This finding suggests that adequate vitamin C transport is particularly important for neurological resilience when APOE4-mediated inflammation is present.

Large-scale blood cell GWAS data add a complementary dimension: a trans-ethnic analysis of 746,667 individuals66 a trans-ethnic analysis of 746,667 individuals
Chen MH et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell, 2020 identified rs1279683 as a genome-wide significant signal for mean corpuscular volume (MCV, p = 3×10⁻²²) and mean corpuscular hemoglobin (MCH, p = 3×10⁻¹⁹). Vitamin C supports iron absorption and erythropoiesis — impaired SVCT2 function may reduce intracellular ascorbate available to erythroblasts, subtly affecting red cell development.

Practical Actions

The G allele at rs1279683 is the population-common allele, present at ~69% in Europeans, so GG homozygosity affects roughly 1 in 3 people of European descent. The vitamin C deficit is moderate — GG homozygotes in the Zanon-Moreno cohort averaged about 9–11 µg/ml versus 11–12 µg/ml for other genotypes. This is clinically meaningful at the margin: suboptimal plasma vitamin C is defined below ~28 µmol/L (approximately 5 µg/ml), and GG homozygotes cluster at the lower end of the adequate range. Consistently high dietary or supplemental vitamin C intake can offset the reduced transport efficiency by increasing the plasma substrate available for SVCT2.

Glaucoma management for G allele carriers does not replace standard monitoring but adds a modifiable risk factor: regular intraocular pressure measurement and a confirmed adequate vitamin C status. High-dose vitamin C (1,000–2,000 mg/day) has been shown in small trials to reduce intraocular pressure in some individuals; while not yet a clinical standard, it is a low-risk intervention for GG homozygotes with a family history or borderline IOP.

Interactions

rs1279683 acts in parallel with rs6053005, another intronic SLC23A2 variant associated with plasma vitamin C in the EPIC cohort. Both variants influence SVCT2-mediated tissue delivery; their combined effect has not been formally studied but is likely additive given their independent signals in the same gene. rs6133175, an SLC23A2 variant associated with preeclampsia and also independently predictive of plasma vitamin C, is a third independent signal at this locus.

The interaction with APOE4 (rs429358) is the most clinically significant: GG homozygotes who also carry APOE4 face a compounded risk — APOE4 increases neuroinflammation and oxidative burden in the brain while GG reduces the SVCT2 capacity to supply ascorbate for antioxidant defence. This combination warrants particular attention to optimizing vitamin C status. Propose for compound action: GG × APOE4 → augmented vitamin C supplementation and cognitive monitoring.

Nutrient Interactions

vitamin C altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Optimal SVCT2 Function Beneficial

Protective A/A genotype — higher plasma vitamin C and lower glaucoma risk

The A allele at rs1279683 is associated with higher SVCT2 expression or activity compared to the G allele. In the Zanon-Moreno 2011 study, non-GG individuals (AA and AG combined) had plasma vitamin C averaging 10.5 µg/ml in glaucoma cases and 12.1 µg/ml in controls — substantially higher than GG homozygotes. In the Hayashi 2021 cognitive decline study, A allele carriers who also carried APOE4 were at lower cognitive decline risk than GG/APOE4 combinations (OR 2.02 for GG vs A-carrier within the APOE4 group), suggesting the A allele confers neurological resilience.

As an AA homozygote, your intraocular ascorbate gradient — which protects the trabecular meshwork from oxidative stress and helps regulate intraocular pressure — is maintained by efficient SVCT2 transport. Your erythrocyte indices (MCV, MCH) are also expected to be unaffected by any SVCT2-related limitation on ascorbate supply to erythroblasts.

AG One G Allele Intermediate

One G allele — modestly reduced vitamin C transport efficiency

As a heterozygote, you have one A allele contributing to normal SVCT2 expression and one G allele with potentially reduced expression or splicing efficiency. The per-allele effect on plasma vitamin C at this locus has not been quantified separately for AG vs AA genotypes in published studies — the Zanon-Moreno data compares GG to non-GG combined. Given the additive inheritance pattern across the SLC23A2 locus, AG heterozygotes are expected to have intermediate plasma vitamin C levels between AA and GG.

From the GWAS data, the G allele also has additive effects on erythrocyte indices (MCV, MCH). AG individuals may have a modest shift in these parameters relative to AA homozygotes, though the per-allele effect size is small (~0.019 SD units per G allele).

GG Two G Alleles Reduced

Two G alleles — reduced plasma vitamin C and increased glaucoma risk

The GG genotype at rs1279683 reduces SVCT2-mediated ascorbate delivery to tissues that concentrate vitamin C 10–100× above plasma. The retina and aqueous humor of the eye depend on SVCT2 in the ciliary epithelium to maintain a high-ascorbate microenvironment that protects against oxidative damage to the trabecular meshwork — the tissue that regulates intraocular pressure. Lower aqueous humor vitamin C concentrations have been directly measured in carriers of SLC23A2 loss-of-function variants (Senthilkumari 2014, PMID 24815519), providing a plausible mechanism for the GG → glaucoma risk link.

In the Hayashi 2021 cognitive decline study of 393 Japanese subjects, GG homozygotes who also carried APOE4 had an OR of 2.02 for cognitive impairment (95% CI 1.05–3.87) compared to APOE4 carriers with at least one A allele. This suggests that adequate vitamin C transport is particularly important for neurological resilience under conditions of elevated oxidative and inflammatory stress.

Large-scale GWAS data (N = 746,667) confirm rs1279683 as a genome-wide significant locus for mean corpuscular volume and mean corpuscular hemoglobin, consistent with vitamin C's role in iron reduction and erythropoiesis. GG homozygotes show slightly smaller, less hemoglobin-rich red cells on average, though the per-allele effect (0.018–0.019 SD) is below clinical detection thresholds in any individual.